Efferocytosis promoter
Kaempferide in propolis or its extracts addresses the lack of effective efferocytosis promotion, enhancing immune regulation and reducing inflammation by removing dead cells.
Patent Information
- Application Number
- JP2023073266
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-04-27
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments do not effectively promote efferocytosis, leading to accumulation of dead cells and associated diseases due to increased generation or decreased efferocytosis function.
Utilizing kaempferide contained in propolis or its extracts as an active ingredient to promote efferocytosis, which is a form of phagocytosis that removes dead cells.
Promotes efferocytosis, thereby regulating the immune system and reducing inflammation, effectively removing dead cells and alleviating associated diseases.
Smart Images

Figure 2024158237000002 
Figure 2024158237000003 
Figure 2024158237000004
Abstract
Description
[Technical field]
[0001] The present invention relates to an efferocytosis promoter. [Background technology]
[0002] In the body, various cells differentiate and divide repeatedly, constantly producing new cells. On the other hand, cell death by apoptosis is induced in cells that have reached the end of their life span or that are injured. Dead cells are purified by phagocytosis of nearby fibroblasts and macrophages, a phenomenon called efferocytosis. Efferocytosis is one of various forms of phagocytosis, but unlike phagocytosis of red blood cells, it targets dead cells and is induced by signals mediated by phosphatidylserine (PS) presented on the surface of the dead cells. In addition, if dead cells are not properly removed, they become secondarily necrotic cells, which release their contents into the surrounding area as the cells are destroyed, causing an inflammatory response (Non-Patent Document 1). In this way, efferocytosis functions constantly to remove dead cells that are constantly occurring.
[0003] However, when the generation of dead cells increases due to tissue damage, inflammation, aging, etc., and exceeds the capacity of normal efferocytosis, dead cells are not removed and accumulate. Furthermore, a decrease in the efferocytosis function itself leads to similar results. Since the accumulation of dead cells is related to the cause and exacerbation of various diseases, it is thought that promoting efferocytosis and suppressing the accumulation of dead cells will lead to the alleviation and cure of diseases. [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Morioka et al, Immunity, 2019,50(5), p.1149-1162 Summary of the Invention [Problem to be solved by the invention]
[0005] However, a method for treating diseases targeting the promotion of efferocytosis has not yet been established. An object of the present invention is to provide a novel efferocytosis promoter. [Means for solving the problem]
[0006] The present inventors have unexpectedly found that kaempferide contained in propolis and its extracts has the effect of promoting efferocytosis. The present invention is based on this novel finding.
[0007] The present invention provides an efferocytosis promoter containing at least one selected from the group consisting of propolis and an extract thereof as an active ingredient.The present invention also provides a method for promoting efferocytosis, comprising administering an effective amount of at least one selected from the group consisting of propolis and an extract thereof to a subject in need thereof.
[0008] The present invention provides an agent for promoting the removal of dead cells, which contains at least one selected from the group consisting of propolis and its extracts as an active ingredient.The present invention also provides a method for promoting the removal of dead cells, which comprises administering to a subject in need thereof an effective amount of at least one selected from the group consisting of propolis and its extracts.
[0009] In the present invention, at least one selected from the group consisting of propolis and extracts thereof may be kaempferide.
[0010] The present invention provides an immune system regulator or anti-inflammatory agent based on the efferocytosis-promoting activity, which comprises at least one member selected from the group consisting of propolis and extracts thereof as an active ingredient.
[0011] The present invention provides a pharmaceutical, quasi-drug, or food composition containing the above-mentioned efferocytosis promoter or dead cell removal promoter. Effect of the Invention
[0012] According to the present invention, there is provided an efferocytosis promoter containing at least one selected from the group consisting of propolis and its extracts as an active ingredient. Also, according to the present invention, there is provided an agent for promoting removal of dead cells containing at least one selected from the group consisting of propolis and its extracts as an active ingredient. [Brief description of the drawings]
[0013] [Figure 1] FIG. 2 is a diagram showing the results of evaluation of the efferocytosis-promoting activity of Brazilian green propolis in fibroblasts (LR73 cells) in Test Example 1. [Diagram 2] FIG. 2 shows the results of evaluation of the efferocytosis-promoting activity of Brazilian green propolis in mouse peritoneal macrophages (pMacs) in Test Example 1. [Diagram 3] FIG. 1 shows the results of evaluation of the efferocytosis-promoting activity of various components contained in Brazilian green propolis in fibroblasts (LR73 cells) in Test Example 2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] Hereinafter, an embodiment of the present invention will be described in detail. However, the present invention is not limited to the following embodiment.
[0015] The efferocytosis promoter according to the present embodiment contains at least one selected from the group consisting of propolis and its extracts as an active ingredient. The dead cell removal promoter according to the present embodiment contains at least one selected from the group consisting of propolis and its extracts as an active ingredient. Hereinafter, the efferocytosis promoter according to the present embodiment and the dead cell removal promoter are collectively referred to as "the agent according to the present embodiment."
[0016] As used herein, "efferocytosis" refers to a form of phagocytosis in which phagocytes such as macrophages remove dead and senescent cells to maintain tissue homeostasis, regulate the immune system, and promote anti-inflammatory effects, and is clearly distinguished from "phagocytosis," a form of phagocytosis in which phagocytes such as macrophages remove bacteria and germs to suppress infectious diseases.
[0017] Propolis is a resinous or waxy substance that constitutes the wall of the hive of a European honeybee. Propolis may be from any place of origin, such as Brazil, China, European countries, Oceania, America, etc., and may be from any plant, such as Alecrin or Eucalyptus. Propolis may be of any rank, such as super green or ultra green. Among these, Brazilian green propolis is preferred because it can obtain a higher efferocytosis effect. The type of honeybee used to collect propolis is not particularly limited. Propolis can be obtained, for example, as a beekeeping product according to a conventional method.
[0018] The propolis may be raw propolis, or may be processed propolis obtained by subjecting raw propolis to crushing, supercritical extraction, water or hydrophilic organic solvent extraction, concentrating or powdering the extract, granulating the powder, etc. Among these, the hydrophilic organic solvent extract obtained by extracting propolis with a hydrophilic organic solvent is preferred because it is an effective ingredient of propolis that is extracted efficiently and in a good balance in a short time. Ethanol is preferred as the hydrophilic organic solvent used for extraction.
[0019] The extraction method for producing the propolis extract is not particularly limited, and examples thereof include a method of extracting at room temperature or by heating using an extraction solvent, a supercritical extraction method using carbon dioxide, etc. As such an extraction solvent, water, an organic solvent, or a water-containing organic solvent can be used, and examples of the organic solvent include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 2-pentanol, and 3-pentanol; ethers such as diethyl ether; esters such as methyl acetate and ethyl acetate; ketones such as acetone; and organic acids such as acetic acid, glacial acetic acid, and propionic acid.
[0020] The propolis extract includes the recovered extract (including further purified extract if necessary), a concentrate obtained by concentrating the extract, and a solid obtained by removing the solvent from the extract by freeze-drying, spray-drying, etc. Here, the concentration, freeze-drying, and spray-drying of the extract can be carried out according to a conventional method.
[0021] Commercially available propolis or its extract may be used. Specific examples of commercially available propolis include Propolis 300 (manufactured by Yamada Bee Farm Co., Ltd.) and Propolis Liquid 30 (manufactured by Yamada Bee Farm Co., Ltd.).
[0022] The content of propolis or an extract thereof in the agent according to the present embodiment may be 10% by mass or more, 15% by mass or more, 17% by mass or more, 20% by mass or more, or 30% by mass or more in terms of solid content relative to the total amount of the agent. The content of propolis in the agent according to the present embodiment may be 40% by mass or less, 30% by mass or less, 25% by mass or less, or 20% by mass or less in terms of solid content relative to the total amount of the agent.
[0023] When the agent according to the present embodiment contains propolis or its extract as an active ingredient, the agent can be used at a dose of 10 mg to 1000 mg, preferably 100 mg to 600 mg, more preferably 150 mg to 350 mg, per day for an adult weighing 60 kg. The dose can be appropriately set within the above range depending on factors such as the health condition of the person taking it, the method of administration, and the combination with other agents.
[0024] Kaempferide is one of the compounds contained in propolis extract and has the following formula: [ka] It is a flavonoid having the structure represented by the following formula:
[0025] The content of kaempferide in the agent according to the present embodiment may be 10% by mass or more, 15% by mass or more, 17% by mass or more, 20% by mass or more, or 30% by mass or more in terms of solid content relative to the total amount of the agent. The content of propolis in the agent according to the present embodiment may be 40% by mass or less, 30% by mass or less, 25% by mass or less, or 20% by mass or less in terms of solid content relative to the total amount of the agent.
[0026] When the agent according to the present embodiment contains kaempferide as an active ingredient, the agent can be used at a dose of 10 mg to 1000 mg per day for an adult weighing 60 kg, preferably at a dose of 100 mg to 600 mg, and more preferably at a dose of 150 mg to 350 mg. The dose can be appropriately set within the above range depending on factors such as the health condition of the person taking it, the method of administration, and the combination with other agents.
[0027] As shown in the Examples below, propolis and its extracts (e.g., kaempferide) have an efferocytosis-promoting effect. Since efferocytosis promotes immune system regulation and anti-inflammatory effects, one embodiment of the present invention provides an immune system regulator or anti-inflammatory agent based on the efferocytosis-promoting effect, which contains at least one active ingredient selected from the group consisting of propolis and its extracts.
[0028] The agent according to the present embodiment may be administered orally (ingested) or parenterally. The agent according to the present embodiment may be administered once a day or in multiple doses, such as twice or three times a day, as long as the effective daily dose is within the above-mentioned range.
[0029] The agent according to the present embodiment may further contain other ingredients in addition to the active ingredient. Examples of other ingredients include pharma- ceutically acceptable ingredients (e.g., excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, solubilizers, suspending agents), and food acceptable ingredients (e.g., minerals, vitamins, flavonoids, quinones, polyphenols, amino acids, nucleic acids, essential fatty acids, cooling agents, binders, sweeteners, disintegrants, lubricants, colorants, flavors, stabilizers, preservatives, sustained-release regulators, surfactants, dissolving agents, and wetting agents).
[0030] The agent according to the present embodiment may be in any form such as solid, liquid, paste, etc., and may be in the form of tablets (including plain tablets, sugar-coated tablets, effervescent tablets, film-coated tablets, chewable tablets, troches, etc.), capsules, pills, powders (powder), fine granules, granules, liquids, suspensions, emulsions, syrups, pastes, injections (including the case where the agent is mixed with distilled water or an infusion such as an amino acid infusion or an electrolyte infusion at the time of use to prepare a liquid), etc. These various preparations can be prepared, for example, by mixing the active ingredient with other ingredients as necessary and forming the mixture into the above-mentioned dosage form.
[0031] The agent according to the present embodiment can be used as a medicine, a quasi-drug, or a food composition itself, or as an ingredient in these products. A medicine, a quasi-drug, or a food composition containing the agent according to the present embodiment as an ingredient can be produced, for example, by adding the agent according to the present embodiment to an intermediate product in the production process of these products.
[0032] When the agent according to the present embodiment is used as a food composition or as one of its components, the food composition is preferably one that emphasizes the tertiary function of food, that is, the function of regulating physical condition. Examples of products that emphasize the tertiary function of food include health foods, functional foods, nutritional functional foods, nutritional supplements, supplements, and foods for specified health uses.
[0033] Examples of food compositions include beverages such as soft drinks such as coffee, juice, and tea drinks, milk drinks, lactic acid bacteria drinks, yogurt drinks, carbonated drinks, and alcoholic beverages such as sake, Western liquor, fruit liquor, and honey wine; spreads such as custard cream; pastes such as fruit paste; Western sweets such as chocolate, donuts, pies, cream puffs, gum, jelly, candy, cookies, cakes, and puddings; Japanese sweets such as daifuku, mochi, manju, castella, anmitsu, and yokan; frozen desserts such as ice cream, popsicles, and sorbet; cooked foods such as curry, beef bowl, porridge, miso soup, soup, meat sauce, pasta, pickles, and jam; and seasonings such as dressings, furikake, umami seasonings, and soup bases. EXAMPLES
[0034] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to the following examples.
[0035] [Test Example 1] Evaluation of the efferocytosis-promoting activity of Brazilian green propolis in fibroblasts (LR73 cells) or mouse peritoneal macrophages (pMacs) Fibroblasts (LR73 cells) or mouse peritoneal macrophages (pMacs) were cultured for 12 hours after adding Brazilian green propolis (50 μg / ml) dissolved in DMSO or ethanol. As a control, fibroblasts or pMacs were cultured for 12 hours after adding DMSO or ethanol. As dead cells to be used for evaluating efferocytosis, apoptosis was induced in Jurkat cells, a T cell line, by ultraviolet irradiation and stained with CypHer 5E (Invitrogen). Dead cells were added to the cultured fibroblasts or pMacs and co-cultured for 1 hour to induce efferocytosis. Non-phagocytic Jurkat cells were then washed away, and the number of cells in which efferocytosis was observed (CypHer 5E+) was quantified as the percentage of the total cells by flow cytometry. The results are shown in Figures 1 and 2.
[0036] Figure 1 shows that efferocytosis was promoted approximately 2-fold in fibroblasts treated with propolis compared to the control. Figure 2 shows that efferocytosis was promoted approximately 1.4-fold in pMacs treated with propolis compared to the control.
[0037] [Test Example 2] Evaluation of the efferocytosis-promoting activity of various components contained in Brazilian green propolis in fibroblasts (LR73 cells) Using the ethanol-soluble components (10 μM) of Brazilian green propolis, the efferocytosis-promoting activity of each component was evaluated in the same manner as in Test Example 1. The results are shown in FIG.
[0038] As shown in FIG. 3, only kaempferide was confirmed to have the effect of promoting efferocytosis.
Claims
1. An efferocytosis promoter comprising at least one active ingredient selected from the group consisting of propolis and extracts thereof.
2. An efferocytosis promoter containing kaempferide as an active ingredient.
3. An agent for promoting the removal of dead cells, comprising as an active ingredient at least one member selected from the group consisting of propolis and extracts thereof.
4. An agent for promoting the removal of dead cells, containing kaempferide as an active ingredient.
Citation Information
Patent Citations
Propolis nutritional composition for enhancing immunity and application thereof
CN110973553A
Propolis composition and its granular preparation
JP2003061593A
Antiallergic action of propolis
JP2008214235A
